Precision Psychiatry Symposium Explores Imaging, AI, and Novel Therapies for Schizophrenia

Virginia Tech hosts a symposium focusing on precision psychiatry, spotlighting imaging, biomarkers, and AI to improve schizophrenia treatment.
Key Details
- 1Precision Psychiatry Symposium scheduled for September at Virginia Tech brings together clinicians, researchers, and industry leaders.
- 2Key topics include new schizophrenia drugs, emerging biomarkers, use of artificial intelligence, and advances in neuroimaging.
- 3Discussion of Cobenfy (xanomeline and trospium chloride), a recently FDA-approved drug for schizophrenia.
- 4Fralin Biomedical Research Institute at VTC highlighted for its programs in computational psychiatry, cognitive neuroscience, and human neuroimaging.
- 5Sessions will explore novel treatment approaches, direct neuromodulator measurement, and computational brain models.
- 6Speakers represent academia, biotechnology, and pharmaceutical companies.
Why It Matters

Source
EurekAlert
Related News

HKU Launches Centre for Health AI Research and Translation
The University of Hong Kong has established the Centre for Health AI Research and Translation (CHART) to drive trustworthy, patient-centered AI innovation in healthcare.

Holographic Neural Network Achieves Multi-Task AI via Light-Based Computing
Researchers have developed a holographic neural network using optics to perform multiple AI classification tasks simultaneously without hardware reconfiguration.

Rethinking Multimodal Cardiovascular AI: When Models Should Defer Predictions
A commentary in Medicine Discovery argues cardiovascular AI models must learn to defer predictions when key modalities are missing, as missingness and asynchrony are clinical realities.